Fourth Quarter 2019 Revenues of $681.0 million, up 6.1% Versus Prior Year Period; up 7.1% on a Constant Currency Basis Fourth Quarter 2019 GAAP Diluted EPS from Continuing Operations of $2.28, up 21.9% Versus Prior Year Period Fourth Quarter 2019 Adjusted Diluted EPS from Continuing Operations of $3.28, up 18.4% […]
Tag: Teleflex
Teleflex Announces Fourth Quarter and Full Year 2019 Earnings Conference Call Information
WAYNE, Pa., Feb. 06, 2020 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that financial results for the fourth quarter and full year 2019 will be released before market open on Thursday, February 20, 2020. An investor conference call will be held at 8:00 a.m. (ET) on Thursday, February […]
Teleflex Receives FDA Clearance for Wattson™ Temporary Pacing Guidewire
WAYNE, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration for the WattsonTM Temporary Pacing Guidewire – the first commercially available bipolar temporary […]
Teleflex Announces Quarterly Dividend
WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 16, 2019 to shareholders of record at the close of business on […]
Teleflex Announces Tenth Anniversary of GuideLiner® Catheter Product Line
Company Celebrates 10 Years of the Industry’s Leading Guide Extension Catheter with More Than 1 Million Units Sold Worldwide WAYNE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the tenth anniversary of its industry-leading GuideLiner® Catheter. Released in November […]
Teleflex Announces Publication of “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device”
WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device.” The SAFE MANTA IDE Clinical Trial, the largest U.S. prospective multi-center study of a purpose-designed large […]
Teleflex to participate at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) 2019 with its complex PCI product portfolio and the newly acquired MANTA™ Vascular Closure Device
WAYNE, Pa., May 15, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, coronary and peripheral interventions, will showcase its complex PCI product portfolio, the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) and the newly acquired MANTA™ Vascular Closure […]
Teleflex Announces Quarterly Dividend
WAYNE, Pa., May 06, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2019 to shareholders of record at the close of business on […]
Teleflex to Present at the Raymond James 40th Annual Institutional Investors Conference
WAYNE, Pa.–(BUSINESS WIRE)–Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 40th Annual Institutional Investors Conference at the JW Marriott Grande Lakes in Orlando, Florida on Tuesday, March 5, 2019 at 4:00 p.m. (ET). A live audio webcast of the conference presentation, along […]
Teleflex Announces U.S. FDA Premarket Approval of MANTA™ Vascular Closure Device
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced that it received premarket approval (PMA) from the U.S. Food and Drug Administration for the MANTA™ Vascular Closure Device – the first commercially available biomechanical vascular closure device designed specifically […]



